Amarin Corporation develops and sells therapeutics for cardiovascular diseases in several countries, including the United States, Canada, and the United Arab Emirates. Its flagship product is VASCEPA, designed to reduce triglyceride levels in patients with severe hypertriglyceridemia. The company collaborates with Mochida Pharmaceutical to develop drug products based on the active ingredient in VASCEPA.